BDBM562819 2-((2S,5R,6S)-6-(3-Chlorophenyl)-5-(4-chlorophenyl)-4-((R)-1-cyanobutyl)-3-oxomorpholin-2-yl)acetic acid and 2-((2R,5S,6R)-6-(3-chlorophenyl)-5-(4-chiorophenyl)-4-((S)-1-cyanobutyl)-3-oxomorpholin-2-yl)acetic acid or 2-((2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-((S)-1-cyanobutyl)-3-oxomorpholin-2-yl)acetic acid and 2-((2R,5S,6R)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-((R)-1-cyanobutyl)-3-oxomorpholin-2-yl)acetic acid::US11407721, Example 66
SMILES CCCC(C#N)N1[C@H]([C@H](O[C@H](CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1
InChI Key InChIKey=XKUYNNZACAGYEX-UHFFFAOYSA-N
Data 2 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 2 hits for monomerid = 562819
Affinity DataIC50: 697nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
Affinity DataIC50: 718nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
